Triterpenes

Compound Class	Triterpenes — C30 isoprenoid compounds; in Ganoderma these are lanostane-type, known collectively as ganoderic acids
Representative Members	Ganoderic acid A, ganoderic acid B, ganoderenic acids; over 150 Ganoderma triterpenoids characterized
Botanical Sources	Ganoderma lucidum (reishi; lingzhi)
Plant Part(s)	Fruiting body and spores
Typical Standardisation	Total triterpenes by HPLC or spectrophotometric method; ~10% common commercial range. Requires ethanolic extraction
Primary Applications	Anti-inflammatory and hepatoprotective formulation, antioxidant positioning, adjunct to beta-glucan immune formulations
Claim Strength (Overview)	Emerging — strong and consistent preclinical anti-inflammatory data; clinical translation notably absent
Buy from Herbuno	Triterpenes 10% Powder (Reishi Extract) | Standardized Ganoderma lucidum → Ganoderma Lucidum Reishi Extract Powder →

Name origin: Triterpene denotes a C30 compound built from six isoprene units (tri- + terpene); the Ganoderma-specific members are lanostane-type triterpenoids known collectively as ganoderic acids, named directly for the source genus. Note that this page documents the Ganoderma lanostane triterpenes specifically — a structurally distinct group from the ursane-type triterpenes of Centella asiatica documented separately in this index under Total Triterpenes. Traditional use: Ganoderma lucidum — lingzhi in Chinese, reishi in Japanese — occupies perhaps the most exalted position in East Asian materia medica, documented in the Shennong Ben Cao Jing as a superior-class herb associated with longevity and spiritual potency, historically so scarce in the wild that it was largely reserved for emperors and depicted extensively in Chinese art as a symbol of immortality; its modern availability is entirely a product of 20th-century cultivation techniques. Research trajectory: Reishi research has advanced along two parallel tracks corresponding to its two major bioactive fractions: the water-soluble beta-glucan polysaccharides (documented separately in this index, with human RCT support for immune modulation) and the ethanol-soluble triterpenes documented here, whose research has been dominated by in-vitro and animal anti-inflammatory and anti-cancer work with notably little clinical translation to date. Commercial source: Ganoderma lucidum fruiting-body extract standardized to total triterpene content is the commercial format; critically, triterpenes require ethanolic extraction, whereas the beta-glucan fraction requires aqueous extraction — a single extract cannot be optimally rich in both without dual-extraction processing.

---

Evidence for Triterpenes Applications

The anti-inflammatory evidence for Ganoderma triterpenes is preclinically strong and remarkably consistent. A systematic review and meta-analysis of preclinical evidence covering 23 studies drawn from over 3,000 records found that all included studies reported significant anti-inflammatory effects through reduction of pro-inflammatory markers TNF-α, IL-1β, and IL-6, operating primarily through downregulation of MAPK and TLR-4/NF-κB signalling, with meta-analysis of in-vitro data confirming significant reductions in nitric oxide, IL-6, and TNF-α levels (Systematic Review 2025). Crucially, that review explicitly excluded clinical trials from its scope — because there are essentially none to include — and its authors state directly that future research must prioritize clinical translation, and that bioavailability and long-term toxicity data were notably absent from the current literature. Claim strength: Emerging.

The same review identifies the central obstacle to this compound class with unusual candour: the structural complexity and isomer diversity of Ganoderma triterpenes remain significant barriers to pharmacological standardization. With over 150 individual ganoderic acids and related triterpenoids characterized, a "total triterpenes 10%" specification conveys aggregate load but almost nothing about which specific triterpenoids are present — a problem materially worse than for most compound classes in this index, and one that directly impedes reproducible clinical research. Claim strength: Emerging (standardization constraint).

Clinical work on reishi as a whole has been more encouraging than the triterpene-specific picture, but the distinction matters: the strongest human reishi evidence — a randomized controlled trial finding enhanced T-lymphocyte populations and improved CD4/CD8 ratio over 84 days — used a β-glucan-standardized preparation, not a triterpene-standardized one (Foods 2023). This is precisely the kind of conflation formulators must avoid: reishi’s human immune-modulation evidence belongs to its polysaccharide fraction, and should not be borrowed to substantiate a triterpene-standardized product. Claim strength: Moderate (for the beta-glucan fraction, not the triterpene fraction).

Ganoderic acids have been extensively investigated for direct anti-proliferative and cytotoxic activity against a wide range of cancer cell lines, with proposed mechanisms including apoptosis induction, MAP-kinase pathway activation, and anti-angiogenic effects. This body of work is scientifically substantial but remains entirely at the preclinical level for the isolated triterpene fraction, and must not be represented in any consumer- or formulator-facing claim as evidence of clinical anticancer benefit. Claim strength: Emerging (preclinical only).

A practical drug-interaction consideration has emerged from the pharmacology literature: Ganoderma triterpenoids can inhibit certain cytochrome P450 enzymes, which has direct implications for potential interactions between reishi products and prescription medications metabolized through those pathways. This mechanistic finding warrants standard caution language on triterpene-standardized products rather than being treated as a purely theoretical concern. Claim strength: Emerging (safety-relevant).

---

Dosage & Formulator Specification

Herbuno carries Ganoderma lucidum extract standardized to 10% total triterpenes, alongside a range of unstandardized reishi formats (extract powder, dehydrated fruiting-body slices, water-soluble liquid extract) and a separately standardized reishi beta-glucan grade. Buyers should be deliberate about which fraction their formulation objective requires: triterpene standardization requires ethanolic extraction and delivers the anti-inflammatory/hepatoprotective constituent profile, while beta-glucan standardization requires aqueous extraction and delivers the immune-modulatory profile with the stronger human evidence base.

Human dosing data for triterpene-standardized reishi extract specifically is, candidly, not well established — a direct consequence of the near-total absence of clinical trials on this fraction noted in the evidence section. Commercial reishi products commonly deliver extract doses in the range of several hundred milligrams to a few grams daily, but formulators should not represent any serving size as clinically validated for the triterpene fraction, and should be transparent that dose selection rests on traditional use and preclinical extrapolation rather than human dose-response data.

Analytical verification should specify total triterpene content by HPLC or spectrophotometric method, and — given the acknowledged standardization difficulty arising from over 150 characterized triterpenoids and their isomer diversity — should ideally include a marker-compound fingerprint (ganoderic acid A being the most commonly used reference standard). Where a product is positioned on reishi’s full activity profile, beta-glucan content should be co-specified, as a single-solvent extract will not be optimally rich in both fractions.

Reishi has an extensive history of traditional use and is generally well tolerated, with mild digestive upset, dry mouth, and dizziness being the most commonly reported adverse effects. Two formulator cautions warrant explicit mention: the cytochrome P450 inhibition noted above creates plausible drug-interaction potential warranting caution alongside prescription medication; and reishi has been reported to have mild antiplatelet activity, warranting standard caution alongside anticoagulant medication and before surgery. Long-term toxicity data for the isolated triterpene fraction is, per the systematic review cited above, notably absent from the literature.

---

Frequently Asked Questions — Triterpenes

Are reishi triterpenes and reishi beta-glucans the same thing?
No, and confusing them is a common and consequential error. Triterpenes (ganoderic acids) are ethanol-soluble and drive the anti-inflammatory and hepatoprotective activity; beta-glucans are water-soluble polysaccharides that drive immune modulation. They require different extraction solvents, and reishi's strongest human clinical evidence belongs to the beta-glucan fraction, not the triterpenes.

Is there human clinical evidence for Ganoderma triterpenes specifically?
Very little. A 2025 systematic review of Ganoderma triterpene anti-inflammatory activity examined only preclinical studies because clinical trials on this fraction are essentially absent. The review authors explicitly call for clinical translation and note that bioavailability and long-term toxicity data are missing from the literature.

Why is standardizing Ganoderma triterpenes so difficult?
Over 150 individual ganoderic acids and related triterpenoids have been characterized, with substantial isomer diversity. A "total triterpenes 10%" figure conveys aggregate load but very little about which specific compounds are present, which researchers have identified as a significant barrier to pharmacological standardization and reproducible clinical research.

Can reishi triterpene supplements interact with medication?
Potentially. Ganoderma triterpenoids have been shown to inhibit certain cytochrome P450 enzymes, creating plausible interaction potential with prescription drugs metabolized through those pathways. Reishi has also been reported to have mild antiplatelet activity, warranting caution alongside anticoagulants and before surgery.

Related compounds: Beta-Glucans, Lentinan, Ursolic Acid, Lupeol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery